Cornercap Investment Counsel Inc. Sells 491 Shares of Hologic, Inc. (NASDAQ:HOLX)

Cornercap Investment Counsel Inc. lessened its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 26,316 shares of the medical equipment provider’s stock after selling 491 shares during the period. Cornercap Investment Counsel Inc.’s holdings in Hologic were worth $1,954,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Innealta Capital LLC acquired a new position in Hologic during the 2nd quarter worth about $25,000. iA Global Asset Management Inc. acquired a new position in Hologic during the 1st quarter worth $37,000. Mather Group LLC. acquired a new position in Hologic during the 1st quarter worth $48,000. Massmutual Trust Co. FSB ADV boosted its position in Hologic by 24.7% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after buying an additional 137 shares during the last quarter. Finally, Toth Financial Advisory Corp increased its stake in shares of Hologic by 81.1% in the 1st quarter. Toth Financial Advisory Corp now owns 775 shares of the medical equipment provider’s stock valued at $60,000 after buying an additional 347 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently issued reports on HOLX shares. Evercore ISI raised their price target on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a report on Tuesday, July 30th. StockNews.com raised shares of Hologic from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Needham & Company LLC reiterated a “buy” rating and set a $90.00 price target on shares of Hologic in a research report on Tuesday, July 30th. JPMorgan Chase & Co. increased their price objective on shares of Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a report on Tuesday, July 30th. Finally, Stephens reaffirmed an “overweight” rating and issued a $92.00 price objective on shares of Hologic in a research note on Tuesday, July 30th. Four analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Hologic presently has an average rating of “Moderate Buy” and a consensus price target of $87.60.

Hologic Stock Down 2.4 %

HOLX stock opened at $80.01 on Thursday. The business has a 50-day moving average of $79.92 and a 200-day moving average of $76.76. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $84.67. The stock has a market capitalization of $18.67 billion, a P/E ratio of 40.82, a P/E/G ratio of 2.58 and a beta of 0.98. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.04. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The business’s quarterly revenue was up 2.7% on a year-over-year basis. During the same period last year, the business earned $0.93 EPS. On average, sell-side analysts anticipate that Hologic, Inc. will post 4.09 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Benjamin Jordan Cohn sold 5,093 shares of Hologic stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the sale, the insider now owns 10,476 shares of the company’s stock, valued at $858,927.24. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the transaction, the director now owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Benjamin Jordan Cohn sold 5,093 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the completion of the sale, the insider now directly owns 10,476 shares in the company, valued at $858,927.24. The disclosure for this sale can be found here. Insiders have sold 18,280 shares of company stock valued at $1,469,973 in the last three months. 1.75% of the stock is currently owned by corporate insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.